相关实验视频
Updated: Jul 12, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
现实世界的数据分析,以确定血糖控制与危急病患者的死亡率之间的关联
Ilias Kalamaras1, George Dafoulas2, Alexandra Bargiota2
1Informatics and Telematics Institute, Centre for Research and Technology Hellas, Thermi Thessaloniki, Greece.
Health informatics journal
|October 21, 2023
概括
维持最佳血糖水平对于重症患者至关重要. 这项研究表明,长时间的高或低血糖增加了重症监护室的死亡率,并降低了生存率.
科学领域:
- 关键护理医学 关键护理医学
- 内分泌学 在内分泌学.
- 医疗信息学 医疗信息学
背景情况:
- 临床研究表明,危急病患者的血糖控制在临床研究中显示出不同的结果.
- 目前的指导方针建议血糖目标为140-180 mg/dL,个性化较低的目标.
- 在大型前性研究中,益处的可重复性仍然是一个挑战.
研究的目的:
- 用现实数据评估血糖控制对重症患者死亡率的影响.
- 提供更多关于葡萄糖变异性与患者结局之间的关联的证据.
- 分析在特定葡萄糖范围内的时间与重症监护室 (ICU) 死亡率之间的关系.
主要方法:
- 使用密集护理IV (MIMIC-IV) 数据库的医疗信息中心进行回顾性分析.
- 血糖控制的特点是,血糖测量时间的百分比在预定义的频段内.
- 使用后勤回归,生存分析和基于机器学习的可视化来分析数据.
主要成果:
- 在低血糖和高血糖范围内度过的时间增加与更高的ICU死亡率有关.
- 在目标葡萄糖范围之外的较长时间与患者存活率下降相关.
- 数据可视化支持了统计分析的发现.
结论:
- 现实世界的数据表明,长时间偏离目标血糖水平会对重症患者的结果产生负面影响.
- 优化血糖控制,最大限度地减少低血糖和高血糖的时间,可能是改善生存的关键.
- 对精确的血糖目标和管理策略的进一步研究是有必要的.
相关概念视频
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
Diabetes: Symptoms, Diagnosis, and Complications
557
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
557
Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
Glucose Homeostasis: Regulation of Blood Glucose
1.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.7K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192

